List view / Grid view
Abbott announced today CE Marking (Conformité Européenne) for a testosterone assay with improved sensitivity and clinical utility. With a simple blood test, the ARCHITECT 2nd Generation Testosterone Assay can accurately measure the wide range of testosterone levels seen in a number of different patient populations and clinical settings.
27 August 2012 | By Gilead Sciences
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved StribildTM...
27 August 2012 | By Boehringer Ingelheim
40,000 people estimated to be saved from a stroke related to non-valvular atrial fibrillation...
27 August 2012 | By Boehringer Ingelheim
New data to be presented at the Annual Congress of the ERS 2012...
27 August 2012 | By Roche
Pivotal study met co-primary efficacy endpoint of overall survival...
26 August 2012 | By Eli Lilly and Company
Study did not meet primary objective of demonstrating prasugrel superiority over clopidogrel in this patient population...
26 August 2012 | By Merck
Merck provided an update on the development programs for vorapaxar, extended release niacin/laropirprant and anacetrapib...
26 August 2012 | By Novartis
Novartis announced results from the Phase II PARAMOUNT study...
24 August 2012 | By GlaxoSmithKline
GSK confirms its intention to commence global filings from the end of 2012...
24 August 2012 | By Boehringer Ingelheim
Indirect comparison based on the RE-LY® trial and the Rocket AF trial suggests advantages of Pradaxa® in stroke prevention in patients with atrial fibrillation...
23 August 2012 | By GlaxoSmithKline
“The start of the Phase III programme in rheumatoid arthritis is an important milestone in our collaboration with Janssen Biologics.”
22 August 2012 | By Daiichi Sankyo
Inavir® Dry Powder Inhaler significantly reduces the incidence of influenza infection...
22 August 2012 | By H. Lundbeck A/S
Lundbeck has appointed Andreas Eggert as senior vice president for global product strategy and Klaus Abel as vice president...
21 August 2012 | By Pfizer
The U.S. FDA has extended the action date by three months for the NDA for tofacitinib...
21 August 2012 | By ANDREW LLOYD & ASSOCIATES
CTO appointment reinforces senior management expertise in biomarker industry...
